Micafungin in the treatment of invasive candidiasis and invasive aspergillosis

Review

(3765) Views  (1628) Full article downloads

Authors: Nathan P Wiederhold, Jason M Cota, Christopher R Frei

Published Date January 2009 Volume 2008:1 Pages 63 - 77

DOI: http://dx.doi.org/10.2147/IDR.S3864

Nathan P Wiederhold¹, Jason M Cota², Christopher R Frei¹

¹University of Texas at Austin College of Pharmacy, Austin, Texas, USA; ²University of the Incarnate Word Feik School of Pharmacy, San Antonio, Texas, USA

Abstract: Micafungin is an echinocandin antifungal agent available for clinical use in Japan, Europe, and the United States. Through inhibition of β-1,3-glucan production, an essential component of the fungal cell wall, micafungin exhibits potent antifungal activity against key pathogenic fungi, including Candida and Aspergillus species, while contributing minimal toxicity to mammalian cells. This activity is maintained against polyene and azole-resistant isolates. Pharmacokinetic and pharmacodynamic studies have demonstrated linear kinetics both in adults and children with concentration-dependent activity observed both in vitro and in vivo. Dosage escalation studies have also demonstrated that doses much higher than those currently recommended may be administered without serious adverse effects. Clinically, micafungin has been shown to be efficacious for the treatment of invasive candidiasis and invasive aspergillosis. Furthermore, the clinical effectiveness of micafungin against these infections occurs without the drug interactions that occur with the azoles and the nephrotoxicity observed with amphotericin B formulations. This review will focus on the pharmacology, clinical microbiology, mechanisms of resistance, safety, and clinical efficacy of micafungin in the treatment of invasive candidiasis and invasive aspergillosis.

Keywords: micafungin, echinocandin, Candida, Aspergillus, invasive candidiasis, invasive aspergillosis

Readers of this article also read: